(HR 0.52, 95% CI 0.42-0.63, P < .001 for noninferiority, P < .001 for superiority) and 20.2% in the 150-mg dual-therapy group as compared with 25.7% in the corresponding triple-therapy group, which did not include elderly patients outside the United States (HR 0.72, 95% CI 0.58-...